Dr. Carey on Tailoring Treatment in Triple-Negative Breast Cancer

Lisa A. Carey, MD, professor, UNC Lineberger Comprehensive Cancer Center, discusses tailoring treatment for patients with triple-negative breast cancer (TNBC).

Currently, platnium-based treatments are being explored, but they are still a work in progress, says Carey. Studies are showing promise, but there is a lack of information to prove that their success translates into overall survival for patients.

The future of tailoring treatment, says Carey, is based on the effectiveness of biomarker development—including immune biomarkers. Also, non-cytotoxic options need to be included in the treatment landscape, as there are none currently available.